DIOSynVax
Blood & Organ Banks · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Department of Veterinary Medicine Mading...Website
www.diosvax.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About DIOSynVax
DIOSynVax specializes in customizing vaccine antigen design to enhance global protection against current and future viruses. Utilizing a patented method that integrates computational biology with validation processes, the company identifies optimal Vaccine Antigen Payload (VAP) candidates while building a comprehensive data reservoir to refine its designs. The firm collaborates with leading organizations to advance innovative vaccine solutions aimed at safeguarding global health. DIOSynVax is committed to developing next-generation vaccines that address both present threats and future challenges.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DIOSynVax your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if DIOSynVax has recently received funding, and reach out quickly before it becomes old news!
DIOSynVax, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when DIOSynVax launches new products
Click to see if DIOSynVax had a recent Job posting/layoffs
Earning: See what the market has to say on DIOSynVax recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at DIOSynVax
Funding: Get notified immidiatlly once DIOSynVax has new funding data
Check out if DIOSynVax is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at DIOSynVax
Find 3 more new buyers
Compare Similar Companies to DIOSynVax
Compare insights from companies similar to DIOSynVax, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
DIOSynVax
<$5M
1-10
Private
-
2017
N/A
Company Profile Activity
Activity Insights
DIOSynVax is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
DIOSynVax is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about DIOSynVax.
DIOSynVax Tech Stack
A closer look at the technologies used by DIOSynVax
See more technologies
DIOSynVax News & Media
DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu
CAMBRIDGE, England and SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated by its "First in Human" Coronavirus vaccine trial, to announce its new...DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu
CAMBRIDGE, England and SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated by its "First in Human" Coronavirus vaccine trial, to announce its new...DIOSynVax Unveils Promising Broad Pan-Bird Flu Vaccine Data at Major Influenza Conference
CAMBRIDGE, England, Oct. 7, 2024 /PRNewswire/ -- DIOSynVax, a pioneering clinical-stage biotechnology company specializing in revolutionary broadly protective vaccines, showcased its latest data on a broadly reactive bird-flu vaccine. This research offers significant hope for a vaccine...DIOSynVax Appoints Ron Moss, MD, as CEO
CAMBRIDGE, England, Oct. 1, 2024 /PRNewswire/ -- DIOSynVax, a pioneering clinical-stage biotechnology company specializing in revolutionary broadly protective vaccines, is thrilled to announce the appointment of Ron Moss MD, as its new Chief Executive Officer (CEO), reporting to its board...
Read more news
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding DIOSynVax
Sign Up For FreeTo access detailed company insights
DIOSynVax specializes in customizing vaccine antigen design to enhance global protection against current and future viruses. Utilizing a patented method that integrates computational biology with validation processes, the company identifies optimal Vaccine Antigen Payload (VAP) candidates while building a comprehensive data reservoir to refine its... Read More
